Healthcare [ 3/11 ] | Biotechnology [ 47/154 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 22 | -1.24
Decreased by
-31.91%
|
-1.13
Decreased by
-9.73%
|
| Aug 4, 22 | -1.32
Decreased by
-28.16%
|
-1.04
Decreased by
-26.92%
|
| May 5, 22 | -1.20
Decreased by
-42.86%
|
-0.89
Decreased by
-34.83%
|
| Feb 28, 22 | -1.00
Decreased by
-1.01%
|
-0.79
Decreased by
-26.58%
|
| Nov 3, 21 | -0.94
Decreased by
-18.99%
|
2.30
Decreased by
-140.87%
|
| Aug 5, 21 | -1.03
Decreased by
-58.46%
|
-0.86
Decreased by
-19.77%
|
| May 4, 21 | -0.84
Decreased by
-50.00%
|
-0.82
Decreased by
-2.44%
|
| Mar 1, 21 | -0.99
Decreased by
-76.79%
|
-0.78
Decreased by
-26.92%
|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 30.30 M
Increased by
+226.34%
|
-66.20 M
Decreased by
-41.60%
|
Decreased by
-218.48%
Increased by
+56.61%
|
| Jun 30, 22 | 31.30 M
Increased by
+464.53%
|
-70.00 M
Decreased by
-39.20%
|
Decreased by
-223.64%
Increased by
+75.34%
|
| Mar 31, 22 | 24.20 M
Increased by
+336.87%
|
-63.40 M
Decreased by
-54.77%
|
Decreased by
-261.98%
Increased by
+64.57%
|
| Dec 31, 21 | 25.63 M
Increased by
+1.06 K%
|
-53.00 M
Decreased by
-27.56%
|
Decreased by
-206.76%
Increased by
+88.96%
|
| Sep 30, 21 | 9.28 M
Increased by
+22.22%
|
-46.75 M
Decreased by
-51.69%
|
Decreased by
-503.53%
Decreased by
-24.12%
|
| Jun 30, 21 | 5.54 M
Decreased by
-3.54%
|
-50.29 M
Decreased by
-99.35%
|
Decreased by
-907.01%
Decreased by
-106.66%
|
| Mar 31, 21 | 5.54 M
Decreased by
-11.22%
|
-40.96 M
Decreased by
-88.44%
|
Decreased by
-739.51%
Decreased by
-112.26%
|
| Dec 31, 20 | 2.22 M
Decreased by
-54.68%
|
-41.55 M
Decreased by
-97.39%
|
Decreased by
-1.87 K%
Decreased by
-335.54%
|
| Rank | ETF | Shares | Market Value | Weight % in ETF |
|---|
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.